Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on oral antiretroviral therapy: 48-week results of a phase 3, multicentre, randomised, open-label, non-inferiority trial
Chloe Orkin, Rosie Mngqibisa, Juan D. Vélez, Princy Kumar, Dominique L Braun, Andrew Carr, Mark Bloch, Sharon Walmsley, Pablo Tebas, Yoshiyuki Yokomaku, Tracy L. Diamond, Beth Jackson, Karen Eves, Anjana Grandhi, Monica Fuszard, Stephanie O. Klopfer, Luisa M. Stamm, Michelle C Fox, Jason Kim
Topics & Concepts
MedicineHuman immunodeficiency virus (HIV)Reverse-transcriptase inhibitorAntiretroviral therapyInternal medicinePhases of clinical researchPhase (matter)PharmacologyAntiretroviral treatmentVirologyOral administrationOncologyClinical trialMEDLINEPharmacokineticsHIV/AIDS drug development and treatmentHIV-related health complications and treatmentsHIV/AIDS Research and Interventions